-
Discordant SARS-CoV-2 spike protein receptor binding domain IgG and neutralization after B cell depletion. Haematologica (IF 11.047) Pub Date : 2022-08-11 Ariela Noy,Santosha A Vardhana
-
Potent preclinical activity of FLT3-directed chimeric antigen receptor T cell immunotherapy against FLT3-mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica (IF 11.047) Pub Date : 2022-08-11 Lisa M Niswander, Zachary T Graff, Christopher D Chien, John A Chukinas, Christina A Meadows, Lillie C Leach, Joseph P Loftus, M Eric Kohler, Sarah K Tasian, Terry J Fry
Chimeric antigen receptor (CAR) T cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), although relapse due to target antigen loss or downregulation has emerged as a major clinical dilemma. Accordingly, great interest exists in developing CAR T cells directed against alternative leukemia cell
-
Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor-T cell therapy. Haematologica (IF 11.047) Pub Date : 2022-08-11 Susanna Carolina Berger, Boris Fehse, Nuray Akyüz, Maria Geffken, Christine Wolschke, Dietlinde Janson, Nico Gagelmann, Marlene Luther, Dominic Wichmann, Christian Frenzel, Guenther Thayssen, Anna Alegiani, Anita Badbaran, Silke Zeschke, Judith Dierlamm, Nicolaus Kröger, Francis A Ayuk
CD19-specific chimeric antigen receptor (CD19-CAR)-T cell therapies mediate durable responses in late-stage B-cell malignancies, but can be complicated by a potentially severe immune effector cell-associated neurotoxicity syndrome (ICANS). Despite broad efforts, the precise mechanisms of ICANS are not entirely known, and resistance to current ICANSdirected therapies (especially corticosteroids) has
-
Osteoprogenitor SFRP1 prevents exhaustion of hematopoietic stem cells via PP2A-PR72/130-mediated regulation of p300. Haematologica (IF 11.047) Pub Date : 2022-08-11 Franziska Hettler, Christina Schreck, Sandra Romero Marquez, Thomas Engleitner, Baiba Vilne, Theresa Landspersky, Heike Weidner, Renate Hausinger, Ritu Mishra, Rupert Oellinger, Martina Rauner, Ronald Naumann, Christian Peschel, Florian Bassermann, Roland Rad, Rouzanna Istvanffy, Robert A J Oostendorp
Remodeling of the bone marrow microenvironment in chronic inflammation and in aging reduces hematopoietic stem cell (HSC) function. To assess the mechanisms of HSC functional decline and find strategies to counteract these, we established a model in which Sfrp1 gene was deleted in Osterix+ osteolineage cells (OS1Δ/Δ mice). HSCs from these mice showed severely diminished repopulating activity with associated
-
Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic SCT is predictive of subsequent relapse and survival. Haematologica (IF 11.047) Pub Date : 2022-08-04 Kriti Verma, Wayne Croft, Hayden Pearce, Jianmin Zuo, Christine Stephens, Jane Nunnick, Francesca Am Kinsella, Ram Malladi, Paul Moss
Allogeneic stem cell transplantation is used widely in the treatment of hematopoietic malignancy. However relapse of malignant disease is the primary cause of treatment failure and reflects loss of immunological graft versus leukaemia effect. We studied the transcriptional and phenotypic profile of CD8+ T cells in the first month following transplantation and related this to risk of subsequent relapse
-
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission. Haematologica (IF 11.047) Pub Date : 2022-08-04 Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Frédéric Bauduer, Kaddour Chabane, Patrice Chevallier, Pascale Cony-Makhoul, Pascale Flandrin-Gresta, Caroline Le Jeune, Yannick Le Bris, Laurence Legros, Hervé Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Ivan Sloma, Delphine Rea, Franck Emmanuel Nicolini
Not available.
-
ARID5B influences B cell development and function in mouse. Haematologica (IF 11.047) Pub Date : 2022-08-04 Charnise Goodings, Xujie Zhao, Shannon McKinney-Freeman, Hui Zhang, Jun J Yang
There is growing evidence for an inherited basis of susceptibility to childhood acute lymphoblastic leukemia (ALL). Genome-wide association studies by us and others have identified non-coding ALL risk variants at the ARID5B gene locus, but the molecular mechanisms linking ARID5B to normal and malignant hematopoiesis remain largely unknown. Using a Vav1-driven transgenic mouse model, we characterized
-
Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting. Haematologica (IF 11.047) Pub Date : 2022-08-04 Valeria Maria Pinto, Barbara Gianesin, Frédéric B Piel, Filomena Longo, Paolo Rigano, Alessandra Quota, Vincenzo Spadola, Giovanna Graziadei, Filippo Mazzi, Maria Domenica Cappellini, Aurelio Maggio, Antonio Piga, Lucia De Franceschi, Gian Luca Forni
Not available.
-
Mass-spectrometry-based proteomics amyloid typing in clinical practice: state-of-the-art from a French nationwide cohort. Haematologica (IF 11.047) Pub Date : 2022-08-04 Magali Colombat, Margot Gaspard, Mylène Camus, Jessica Dalloux-Chioccioli, Audrey Delas, Elsa Poullot, Anissa Moktefi, Arnaud François, Anne Moreau, Jean-Bapiste Gibier, Pierre Raynaud, Antoine Huart, Alexis Piedrafita, Julia Gilhodes, Olivier Lairez, Gilles Grateau, Sophie Georgin-Lavialle, Hervé Maisonneuve, Philippe Moreau, Arnaud Jaccard, Franck Bridoux, Violaine Plante-Bordeneuve, Thibaud Damy
Not available.
-
Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-08-04 Elise Sourdeau, Ludovic Suner, Mara Memoli, Alexis Genthon, Frédéric Feger, Lou Soret, Nasséra Abermil, Laurence Heuberger, Chrystele Bilhou-Nabera, Hélène Guermouche, Fabrizia Favale, Simona Lapusan, Michael Chaquin, Claire Hirschauer, Mohamad Mohty, Ollivier Legrand, François Delhommeau, Pierre Hirsch
Chemotherapy resistance is the main cause of treatment failure in acute myeloid leukemia (AML) and has been related to ATP-binding cassette (ABC) transporter activity. However, the links between ABC activity, immunophenotype, and molecular AML parameters have been poorly evaluated. Moreover, the prognostic value of ABC activity, when compared to new molecular markers, is unknown. Here we investigated
-
Translational readthrough at F8 nonsense variants in factor VIII B domain contributes to residual expression and lowers inhibitor association. Haematologica (IF 11.047) Pub Date : 2022-08-04 Maria Francesca Testa, Silvia Lombardi, Francesco Bernardi, Mattia Ferrarese, Donata Belvini, Paolo Radossi, Giancarlo Castaman, Mirko Pinotti, Alessio Branchini
In hemophilia A (HA), F8 nonsense variants, and particularly those affecting the large factor VIII (FVIII) B domain that is dispensable for coagulant activity, display lower association with replacement therapy-related anti-FVIII inhibitory antibodies as retrieved from multiple international databases. Since null genetic conditions favour inhibitor development, we hypothesized that translational readthrough
-
Splenectomy in sickle cell disease: do benefits outweigh risks? Haematologica (IF 11.047) Pub Date : 2022-08-04 Amina Nardo-Marino, Valentine Brousse
Not available.
-
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-08-04 Corentin Orvain, Jacob A Wilson, Min Fang, Brenda M Sandmaier, Eduardo Rodríguez-Arbolí, Brent L Wood, Megan Othus, Frederick R Appelbaum, Roland B Walter
Measurable residual disease (MRD) before hematopoietic cell transplantation (HCT) is an independent established prognostic factor in patients with acute myeloid leukemia (AML). Several methods exist to evaluate the presence of residual leukemia cells, but how these are used best in combination is unclear. To examine how residual cytogenetic abnormalities and MRD testing by multiparameter flow cytometry
-
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-08-04 Raffaele Palmieri, Megan Othus, Guang-Shing Cheng, Francesco Buccisano, Giovangiacinto Paterno, Luca Maurillo, Maria Ilaria Del Principe, Giuseppe Sconocchia, Adriano Venditti, Roland B Walter
Not available.
-
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true. Haematologica (IF 11.047) Pub Date : 2022-08-01 Hélène Cavé
-
Images from the Haematologica Atlas of Hematologic Cytology: congenital dyserythropoietic anemia type II. Haematologica (IF 11.047) Pub Date : 2022-08-01 Rosangela Invernizzi
-
Improving the anti-acute myeloid leukemia activity of CD123-specific Engager T cells by MyD88 and CD40 costimulation. Haematologica (IF 11.047) Pub Date : 2022-07-28 Abishek Vaidya, Erin Doherty, Xiya Wu, Sujuan Huang, Nikhil Hebbar, Unmesha Thanekar, Challice L Bonifant, Cheng Cheng, Stephen Gottschalk, M Paulina Velasquez
The outcome of acute myeloid leukemia (AML) remains poor, and immunotherapy has the potential to improve this. T cells expressing chimeric antigen receptors (CARs) or bispecific T cell engagers targeting CD123 are actively being explored in preclinical and/or early phase clinical studies. We have shown that T cells expressing CD123-specific bispecific T cell engagers (CD123.ENG T cells) have anti-AML
-
Analysis of rare driving events in pediatric acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-07-28 Sanne Noort, Jolieke van Oosterwijk, Jing Ma, Elizabeth A R Garfinkle, Stephanie Nance, Michael Walsh, Guangchun Song, Dirk Reinhardt, Martina Pigazzi, Franco Locatelli, Henrik Hasle, Jonas Abrahamsson, Marie Jarosova, Charikleia Kelaidi, Sophia Polychronopoulou, Marry M Van den Heuvel-Eibrink, Maarten Fornerod, Tanja A Gruber, C Michel Zwaan
Elucidating genetic aberrations in pediatric acute myeloid leukemia (AML) provides insight in biology and may impact on risk-group stratification and clinical outcome. This study aimed to detect such aberrations in a selected series of samples without known (cyto)genetic aberration using molecular profiling. A cohort of 161 patients was selected from various study groups: DCOG, BFM, SJCRH, NOPHO and
-
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? Haematologica (IF 11.047) Pub Date : 2022-07-28 Sigrid S Skanland, Jennifer R Brown
Phosphatidylinositol 3-kinase (PI3K) inhibitors are effective in chronic lymphocytic leukemia (CLL). However, the severe toxicity profile associated with the first-generation inhibitors idelalisib and duvelisib, combined with the availability of other more tolerable agents, have limited their use. CLL is still considered incurable, and relapse after treatment, development of resistance, and treatment
-
Getting (T-cells) ENGaged. Haematologica (IF 11.047) Pub Date : 2022-07-28 Susanne H C Baumeister
Not available.
-
Minnesota acute GvHD risk score predicts survival at onset of GvHD after PTCy prophylaxis. Haematologica (IF 11.047) Pub Date : 2022-07-28 Federica Ardizzoia, Francesca Lorentino, Alessandro Bruno, Sarah Marktel, Fabio Giglio, Daniela Clerici, Francesca Farina, Sara Mastaglio, Simona Piemontese, Andrea A Assanelli, Matteo G Carrabba, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri, Raffaella Greco, Maria Teresa Lupo-Stanghellini
Not available.
-
Acute myeloid leukemia early after anti-CD19 chimeric antigen receptor T cells infusion in a patient with refractory diffuse large B cell lymphoma and pre-existing clonal hematopoiesis. Haematologica (IF 11.047) Pub Date : 2022-07-28 Lorenza Falini, Alessandra Venanzi, Valentina Tini, Alessandra Innocente, Stelvio Ballanti, Simonetta Saldi, Silvio Sivolella, Antonio Pierini, Cynthia Aristei, Enrico Tiacci, Vincenzo Maria Perriello, Brunangelo Falini
Not available.
-
Hypercortisolemic Cushing's patients possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis. Haematologica (IF 11.047) Pub Date : 2022-07-21 Lilian Varricchio, Eliza B Geer, Fabrizio Martelli, Maria Mazzarini, Alister Funnell, James J Bieker, Thalia Papayannopoulou, Anna Rita Migliaccio
Although human cultures stimulated with dexamethasone suggest that the glucocorticoid receptor (GR) activates stress erythropoiesis, the effects of GR activation on erythropoiesis in vivo remains poorly understood. We characterized the phenotype of a large cohort of patients with Cushing's Disease, a rare condition associated with elevated cortisol levels. Results from hypercortisolemic patients with
-
Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. Haematologica (IF 11.047) Pub Date : 2022-07-21 Christopher E Jensen, Hilary M Heiling, Konan E Beke, Allison M Deal, Ashley L Bryant, Lorinda A Coombs, Matthew C Foster, Daniel R Richardson
Time at home is a critically important outcome to adults with acute myeloid leukemia (AML) when selecting treatment; however, no study to date has adequately described the amount of time older adults spend at home following initiation of chemotherapy. We queried records from a multi-institution health system to identify adults age ≥60 newly diagnosed with AML treated with azacitidine (AZA) or venetoclax
-
Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica (IF 11.047) Pub Date : 2022-07-21 Valerio De Stefano, Alessandra Larocca, Monica Carpenedo, Michele Cavo, Francesco Di Raimondo, Anna Falanga, Massimo Offidani, Maria Teresa Petrucci, Marco Ruggeri, Roberto Mario Santi, Giovanni Barosi
The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved the outcomes of patients but, in parallel, has changed the frequency and epidemiology of thrombotic events. Now, thrombosis is a significant cause of morbidity and mortality in MM patients, and optimal thromboprophylaxis is far from being
-
The effects on erythropoiesis of chronic glucorticoid stimulation in Cushing's syndrome. Haematologica (IF 11.047) Pub Date : 2022-07-21 John Strouboulis, Sara El Hoss
Not available.
-
Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest? Haematologica (IF 11.047) Pub Date : 2022-07-21 Ehab Atallah
Not available.
-
Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome. Haematologica (IF 11.047) Pub Date : 2022-07-21 Igor Giarretta, Walter Ageno, Francesco Dentali
Not available.
-
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T cell exhaustion. Haematologica (IF 11.047) Pub Date : 2022-07-14 Joseph G Taylor, Edward Truelove, Andrew Clear, Maria Calaminici, John G Gribben
Classical Hodgkin Lymphoma (CHL) is unusually sensitive to PD1 inhibition and PDL1 is highly expressed on CHL cells and in the tumor microenvironment. This could be interpreted as evidence of exhaustion, but paradoxically, PD1+ lymphocyte infiltration does not predict PD1 inhibitor response and no increase in cytotoxic markers is seen after PD1 therapy as might be expected with reversal of exhaustion
-
RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-07-14 Hualei Zhang, Baohuan Cai, Yun Liu, Yating Chong, Atsuko Matsunaga, Stephanie Fay Mori, Xuexiu Fang, Eiko Kitamura, Chang-Sheng Chang, Ping Wang, John K Cowell, Tianxiang Hu
The Philadelphia (Ph) 9;22 chromosome translocation has two common isoforms that are preferentially associated with distinct subtypes of leukemia. The p210 variant is the hallmark of CML whereas p190 is frequently associated with B-ALL. The only sequence difference between the two isoforms is the guanidine exchange factor (GEF) domain. This GEF is reported to activate RHO family GTPases in response
-
Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. Haematologica (IF 11.047) Pub Date : 2022-07-14 Megan Othus, Guillermo Garcia-Manero, John E Godwin, James K Weick, Frederick R Appelbaum, Harry P Erba, Elihu H Estey
We have previously shown that complete response (CR) rates and overall survival (OS) of patients with acute myeloid leukemia (AML) have improved since the 1980s. However, we have not previously evaluated how the length of first CR (CR1) has changed over this time period. To address this, we analyzed 1,247 patients age 65 or younger randomized to 7+3 arms from 5 SWOG studies: S8600 (n=530), S9031 (n=98)
-
Histological, genetic characterization and follow-up of 130 patients with chronic triplenegative thrombocytosis. Haematologica (IF 11.047) Pub Date : 2022-07-14 Sandrine Lemoine, Clelia Mornet, Isabelle Quintin-Roue, Marie-Christine Rousselet, Laurane Cottin, Aurélie Georgeais, Ludovic Dubouis, Françoise Boyer, Corentin Orvain, Clara Caillon, Maxime Renard, Valoris Le Brun, Lenaig Le Clech, Jean-Christophe Ianotto, Emmanuelle Génin, Barbara Burroni, Valérie Ugo, Damien Luque Paz, Eric Lippert
Not available.
-
Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica (IF 11.047) Pub Date : 2022-07-14 Deborah M Stephens, Hongli Li, Louis S Constine, Thomas J Fitzgerald, John P Leonard, Brad S Kahl, Joo Y Song, Michael L LeBlanc, Sonali M Smith, Daniel O Persky, Jonathan W Friedberg
Not available.
-
Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. Haematologica (IF 11.047) Pub Date : 2022-07-14 Nathalie Forgeard, Marine Baron, Jonathan Caron, Clementine Boccon-Gibod, Daphne Krzisch, Nayara Guedes, Veronique Morel, Nathalie Jacque, Maya Ouzegdouh, Sylvain Choquet, Clotilde Bravetti, Florence Nguyen-Khac, Elise Chapiro, Veronique Leblond, Damien Roos-Weil
Not available.
-
CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Haematologica (IF 11.047) Pub Date : 2022-07-14 Maher K Gandhi, Colm Keane
Not available.
-
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica (IF 11.047) Pub Date : 2022-07-14 Joanna Zurko, Jeremy Ramdial, Mazyar Shadman, Sairah Ahmed, Aniko Szabo, Lorenzo Iovino, Ana Alarcon Tomas, Craig Sauter, Miguel-Angel Perales, Nirav N Shah, Utkarsh H Acharya, Caron Jacobson, Robert J Soiffer, Trent Wang, Krishna V Komanduri, Samantha Jaglowski, Adam S Kittai, Nathan Denlinger, Madiha Iqbal, Mohamed A Kharfan-Dabaja, Ernesto Ayala, Julio Chavez, Michael Jain, Frederick L Locke, Yazeed
Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T-cell therapy (CAR-T). Nonetheless, data on the efficacy and toxicities of alloHCT after receipt of CAR-T are limited. We report a multicenter retrospective study assessing the safety, toxicities, and outcomes of alloHCT
-
Maintaining osteoclastogenesis following allogeneic hematopoietic stem cell transplantation for osteopetrosis: evidence from in vitro testing. Haematologica (IF 11.047) Pub Date : 2022-07-07 Süreyya Savaşan, Manisha Gadgeel, Cathryn Freeman, Omar Moussa
Not available.
-
Platelet functional abnormalities and clinical presentation in pediatric patients with germline RUNX1, ANKRD26, and ETV6 mutations. Haematologica (IF 11.047) Pub Date : 2022-07-07 Galina S Ovsyannikova, Daria V Fedorova, Ivan P Tesakov, Alexey A Martyanov, Anastasia A Ignatova, Evgeniya A Ponomarenko, Pavel A Zharkov, Anna V Pavlova, Elena V Raykina, Michael A Maschan, Mikhail A Panteleev, Galina A Novichkova, Anastasia N Sveshnikova, Nataliya S Smetanina
Not available.
-
Comparative analysis of oral and intravenous iron therapy in rat models of inflammatory anemia and iron deficiency. Haematologica (IF 11.047) Pub Date : 2022-07-07 Lara Valente De Souza, Alexander Hoffmann, Christine Fischer, Verena Petzer, Malte Asshoff, Igor Theurl, Piotr Tymoszuk, Markus Seifert, Natascha Brigo, Richard Hilbe, Egon Demetz, Laura Von Raffay, Sylvia Berger, Marina Barros-Pinkelnig, Guenter Weiss
Anemia is a major health issue and associated with increased morbidity. Iron deficiency anemia (IDA) is the most prevalent, followed by anemia of chronic disease (ACD). IDA and ACD often coexist, challenging diagnosis and treatment. While iron supplementation is the first-line therapy for IDA, its optimal route of administration and the efficacy of different repletion strategies in ACD are elusive
-
Association of FLT3-ITD length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis. Haematologica (IF 11.047) Pub Date : 2022-07-07 Tobias B Polak, Joost Van Rosmalen, Stijn Dirven, Julia K Herzig, Jacqueline Cloos, Soheil Meshinchi, Konstanze Döhner, Jeroen J W M Janssen, David G J Cucchi
Not available.
-
Graft-versus-host disease in allogeneic transplantation: the good and the bad. Haematologica (IF 11.047) Pub Date : 2022-07-01 Nicolaus-Martin Kröger
-
Images from the Haematologica Atlas of Hematologic Cytology: parvovirus-induced pure red cell aplasia. Haematologica (IF 11.047) Pub Date : 2022-07-01 Rosangela Invernizzi
-
Plasma cell leukemia: another piece of the puzzle. Haematologica (IF 11.047) Pub Date : 2022-06-30 Pellegrino Musto, Ralph Wäsch
Not available.
-
Double punch for plasma cell leukemia. Haematologica (IF 11.047) Pub Date : 2022-06-30 Martin Kaiser
Not available.
-
Clinical features of hepatitis E infections in patients with hematological disorders. Haematologica (IF 11.047) Pub Date : 2022-06-30 Susanne Ghandili, Cecilia Lindhauer, Sven Pischke, Julian Schulze Zur Wiesch, Philipp H Von Kroge, Susanne Polywka, Carsten Bokemeyer, Walter Fiedler, Nicolaus Kröger, Francis Ayuk, Raissa Adjallé, Franziska Modemann
Hepatitis E virus is increasingly being reported to cause chronic infection in immunocompromised patients. However, less is known about patients with underlying hematologic disease. In particular, the impact of hepatitis E infection on oncologic therapy has been poorly described. In this retrospective single-center analysis, we analyzed 35 hematological patients with hepatitis E, including 20 patients
-
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia. Haematologica (IF 11.047) Pub Date : 2022-06-30 Naseema Gangat, Isla Johnson, Kristen McCullough, Faiqa Farrukh, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek Mangaonkar, Mark Litzow, William Hogan, Mithun Shah, Mrinal Patnaik, Animesh Pardanani, Ayalew Tefferi
Not available.
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica (IF 11.047) Pub Date : 2022-06-30 Mi Kwon, Gloria Iacoboni, Juan Luis Reguera, Lucía López Corral, Rafael Hernani Morales, Valentín Ortiz-Maldonado, Manuel Guerreiro, Ana Carolina Caballero, María Luisa Guerra Domínguez, Jose Maria Sanchez Pina, Alberto Mussetti, Juan Manuel Sancho, Mariana Bastos-Oreiro, Eva Catala, Javier Delgado, Hugo Luzardo Henriquez, Jaime Sanz, María Calbacho, Rebeca Bailén, Cecilia Carpio, Jose Maria Ribera
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T-cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel
-
Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica (IF 11.047) Pub Date : 2022-06-30 Uday R Popat, Borje S Andersson, Roland Bassett, Jitesh Kawedia, Ben C Valdez, Amin M Alousi, Gheath Al-Atrash, Qaiser Bashir, Chitra M Hosing, Jin S Im, Partow Kebriaei, David Marin, Yago Nieto, Betul Oran, Amanda Olson, Muzaffar H Qazilbash, Samer A Srour, Elizabeth J Shpall, Richard E Champlin, Rohtesh S Mehta
Not available.
-
IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica (IF 11.047) Pub Date : 2022-06-30 Jahanzaib Khwaja, Shirley D'Sa, Monique C Minnema, Marie José Kersten, Ashutosh Wechalekar, Josephine M Vos
IgM monoclonal gammopathy of undetermined significance is a pre-malignant condition for Waldenstrom Macroglobulinaemia (WM) and other B-cell malignancies, defined by asymptomatic circulating IgM monoclonal protein below 30 g/l with a lymphoplasmacytic bone marrow infiltration of less than 10%. A significant proportion, however develop unique immunological and biochemical manifestations related to the
-
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling. Haematologica (IF 11.047) Pub Date : 2022-06-30 Sarah Lawless, Simona Iacobelli, Nina Simone Knelange, Patrice Chevallier, Didier Blaise, Noel Milpied, Roberto Foà, Jan J Cornelissen, Bruno Lioure, Ruben Benjamin, Xavier Poiré, Monique C Minnema, Matthew Collin, Stig Lenhoff, John A Snowden, Stella Santarone, Keith M O Wilson, Fernanda Trigo, Peter Dreger, Lara H Böhmer, Hein Putter, Laurent Garderet, Nicolaus Kröger, Ibrahim Yaukoub-Agha, Stefan
Primary Plasma Cell Leukaemia (pPCL) is a rare and challenging malignancy. There is limited data regarding optimum transplant approaches. Therefore we undertook a retrospective analysis from 1998-2014 of 751 patients with Primary Plasma Cell Leukaemia (pPCL) undergoing one of four transplant strategies; single autologous transplant (single-auto), single allogeneic transplant (allo-first) or a combined
-
Routine clinical parameters and laboratory testing predict therapy related myeloid neoplasms after treatment for breast cancer. Haematologica (IF 11.047) Pub Date : 2022-06-30 Giulia Petrone, Charles Gaulin, Andriy Derkach, Ashwin Kishtagari, Mark E Robson, Rekha Parameswaran, Eytan M Stein
We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and cytopenias who were referred for BMBx between 2002-2018 were identified using the Memorial Sloan Kettering Cancer Center institutional database. Characteristics associated with the risk of t-MN were evaluated
-
Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk between NK cells, monocytes and myeloma cells. Haematologica (IF 11.047) Pub Date : 2022-06-30 Kelden Richardson, Simon P Keam, Joe Jiang Zhu, Deborah Meyran, Criselle D'Souza, Sean Macdonald, Kerry Campbell, Michael Robbins, Natalie A Bezman, Kirsten Todd, Hang Quach, David S Ritchie, Simon J Harrison, H Miles Prince, Joseph A Trapani, Misty R Jenkins, Paul A Beavis, Phillip K Darcy, Paul J Neeson
Patients with refractory relapsed multiple myeloma (RRMM) respond to Elotuzumab (Elo) and lenalidomide (Len) combination treatment. The mechanisms underlying this observation are not fully understood. Furthermore, predictive biomarkers of response have not been revealed to date. To address these issues, we used a humanized myeloma mouse model and adoptive transfer of human NK cells to show that Elo
-
Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia. Haematologica (IF 11.047) Pub Date : 2022-06-23 Peiyuan Dong, Lingyun Chen, Hongfei Wu, Jiali Huo, Zhongxing Jiang, Yingqi Shao, Xiang Ren, Jinbo Huang, Xingxin Li, Min Wang, Neng Nie, Jing Zhang, Peng Jin, Yizhou Zheng, Meili Ge
Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous immature myeloid cells and display immunosuppressive function. In this study, MDSCs populations were evaluated in acquired aplastic anemia (AA) (n=65) in which aberrant immune mechanisms contributed to bone marrow destruction. Our data demonstrate that both the proportion and immunosuppressive function of MDSCs are impaired in AA
-
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low or intermediate-1 risk myelodysplastic syndrome. Haematologica (IF 11.047) Pub Date : 2022-06-23 Rami S Komrokji, Hetty E Carraway, Ulrich Germing, Martin Wermke, Amer M Zeidan, Eric Fu, Björn Rüter, Ute Burkard, Annika Osswald, James M Foran
Not available.
-
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: Subgroup analyses from ICARIA-MM and IKEMA. Haematologica (IF 11.047) Pub Date : 2022-06-23 Tom Martin, Paul G Richardson, Thierry Facon, Philippe Moreau, Aurore Perrot, Ivan Spicka, Kamlesh Bisht, Marlene Inchauspé, France Casca, Sandrine Macé, Helgi Van de Velde, Kenshi Suzuki
Not available.
-
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program. Haematologica (IF 11.047) Pub Date : 2022-06-23 Keren Isaev, Ting Liu, Mehran Bakhtiari, Kit Tong, Rashmi Goswami, Bernard Lam, Ilinca Lungu, Paul M Krzyzanowski, Amit Oza, Neesha Dhani, Anca Prica, Michael Crump, Robert Kridel
Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of tissue that gets sampled during the routine diagnostic process, generally from a single nodal or extranodal site. Furthermore, the trajectory of how lymphoma, and especially non-Hodgkin lymphoma, spreads throughout the human
-
SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia. Haematologica (IF 11.047) Pub Date : 2022-06-23 Sibylle C Mellinghoff, Leonie Mayer, Sandra Robrecht, Leonie M Weskamm, Christine Dahlke, Henning Gruell, Maike Schlotz, Kanika Vanshylla, Hans A Schloser, Martin Thelen, Anna-Maria Fink, Kirsten Fischer, Florian Klein, Marylyn M Addo, Barbara Eichhorst, Michael Hallek, Petra Langerbeins
Not available.
-
Surprise, surprise: STAT5 not enough to stop the steroids. Haematologica (IF 11.047) Pub Date : 2022-06-23 Marta B Fernandes, João T Barata
Not available.
-
Pseudo-progression of adult T-cell leukemia-lymphoma after cord blood transplantation. Haematologica (IF 11.047) Pub Date : 2022-06-23 Shigeo Fuji, Jun-Ichirou Yasunaga, Eri Watanabe, Masao Matsuoka, Kaoru Uchimaru, Jun Ishikawa
Not available.
-
STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of BCL2 and BCLXL following glucocorticoid treatment. Haematologica (IF 11.047) Pub Date : 2022-06-23 Jordy C G Van der Zwet, Valentina Cordo', Jessica G C A M Buijs-Gladdines, Rico Hagelaar, Willem K Smits, Eric Vroegindeweij, Laura T M Graus, Vera Poort, Marloes Nulle, Rob Pieters, Jules P P Meijerink
Physiologic and pathogenic IL7-receptor (IL7R) induced signaling provokes glucocorticoid resistance in a subset of pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients. Activation of downstream STAT5 has been suggested to cause steroid resistance through upregulation of anti-apoptotic BCL2, one of its downstream target genes. Here, we demonstrate that isolated STAT5 signaling in various T-ALL